Eucrates Biomedical Acquisition (EUCR) Short Interest Ratio & Short Volume → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free EUCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Eucrates Biomedical Acquisition Short Interest DataCurrent Short Volume16,800 sharesPrevious Short Volume12,800 sharesChange Vs. Previous Month+31.25%Dollar Volume Sold Short$167,328.00Short Interest Ratio / Days to Cover1.4Last Record DateAugust 15, 2022Outstanding Shares4,210,000 sharesFloat Size10,790,000 sharesShort Percent of Float0.16%Today's Trading Volume12,700 sharesAverage Trading Volume2,287 sharesToday's Volume Vs. Average555% Short Selling Eucrates Biomedical Acquisition ? Sign up to receive the latest short interest report for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEUCR Short Interest Over TimeEUCR Days to Cover Over TimeEUCR Percentage of Float Shorted Over Time Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. Eucrates Biomedical Acquisition Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/15/202216,800 shares $167,328.00 +31.3%0.2%1.4 $9.96 7/31/202212,800 shares $127,232.00 -23.8%0.1%1.3 $9.94 7/15/202216,800 shares $166,824.00 +236.0%0.2%1.6 $9.93 6/30/20225,000 shares $49,500.00 -2.0%0.1%0.5 $9.90 6/15/20225,100 shares $50,439.00 -3.8%0.1%0.3 $9.89 5/31/20225,300 shares $52,311.00 +1.9%0.1%0.3 $9.87 Get the Latest News and Ratings for EUCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eucrates Biomedical Acquisition and its competitors with MarketBeat's FREE daily newsletter. 5/15/20225,200 shares $51,376.00 -34.2%0.1%0.4 $9.88 4/30/20227,900 shares $78,052.00 -18.6%0.1%0.7 $9.88 4/15/20229,700 shares $95,836.00 +61.7%0.1%0.7 $9.88 3/31/20226,000 shares $59,040.00 +1.7%N/A0.4 $9.84 3/15/20225,900 shares $57,997.00 +1.7%0.1%0.6 $9.83 2/28/20225,800 shares $56,956.00 -1.7%0.1%0.6 $9.82 2/15/20225,900 shares $57,879.00 -1.7%0.1%0.7 $9.81 1/31/20226,000 shares $58,620.00 +5.3%0.1%0.3 $9.77 1/15/20225,700 shares $55,860.00 -32.1%N/A0 $9.80 12/31/20218,400 shares $81,984.00 +37.7%0.1%0.4 $9.76 12/15/20216,100 shares $60,085.00 -3.2%0.1%0.3 $9.85 11/30/20216,300 shares $62,055.00 -97.0%0.1%0.3 $9.85 11/15/2021211,800 shares $2.08 million +3,316.1%2.0%9.4 $9.80 10/29/20216,200 shares $60,698.00 -1.6%0.1%0.5 $9.79 10/15/20216,300 shares $61,739.37 +8.6%0.1%0.7 $9.80 9/30/20215,800 shares $56,724.00 -86.9%0.1%0.8 $9.78 9/15/202144,300 shares $432,811.00 +592.2%0.4%8.7 $9.77 8/31/20216,400 shares $61,952.00 -13.5%0.1%1 $9.68 8/13/20217,400 shares $71,632.00 No Change0.1%1.3 $9.68 EUCR Short Interest - Frequently Asked Questions What is Eucrates Biomedical Acquisition's current short interest? Short interest is the volume of Eucrates Biomedical Acquisition shares that have been sold short but have not yet been covered or closed out. As of August 15th, investors have sold 16,800 shares of EUCR short. 0.16% of Eucrates Biomedical Acquisition's shares are currently sold short. Learn More on Eucrates Biomedical Acquisition's current short interest. What is a good short interest ratio for Eucrates Biomedical Acquisition? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EUCR shares currently have a short interest ratio of 1.0. Learn More on Eucrates Biomedical Acquisition's short interest ratio. What is a good short interest percentage for Eucrates Biomedical Acquisition? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.16% of Eucrates Biomedical Acquisition's floating shares are currently sold short. Is Eucrates Biomedical Acquisition's short interest increasing or decreasing? Eucrates Biomedical Acquisition saw a increase in short interest in August. As of August 15th, there was short interest totaling 16,800 shares, an increase of 31.3% from the previous total of 12,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Eucrates Biomedical Acquisition's float size? Eucrates Biomedical Acquisition currently has issued a total of 4,210,000 shares. Some of Eucrates Biomedical Acquisition's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Eucrates Biomedical Acquisition currently has a public float of 10,790,000 shares. How does Eucrates Biomedical Acquisition's short interest compare to its competitors? 0.16% of Eucrates Biomedical Acquisition's shares are currently sold short. Here is how the short interest of companies in the industry of "holding & other investment offices" compare to Eucrates Biomedical Acquisition: Yotta Acquisition Co. (0.02%), ESGEN Acquisition Co. (1.81%), Kairous Acquisition Corp. Limited (0.12%), Digital Health Acquisition Corp. (1.03%), Moringa Acquisition Corp (0.13%), Cetus Capital Acquisition Corp. (0.01%), Integral Acquisition Co. 1 (0.05%), WinVest Acquisition Corp. (0.02%), Qomolangma Acquisition Corp. (0.01%), Arogo Capital Acquisition Corp. (1.58%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Occidental Petroleum Co. ($4.13 billion), Charter Communications, Inc. ($3.94 billion), Coinbase Global, Inc. ($2.38 billion), Lucid Group, Inc. ($2.30 billion), T. Rowe Price Group, Inc. ($2.22 billion), Williams-Sonoma, Inc. ($2.02 billion), Plug Power Inc. ($1.94 billion), Chesapeake Energy Co. ($1.91 billion), Unity Software Inc. ($1.82 billion), and Rivian Automotive, Inc. ($1.74 billion). View all of the most shorted stocks. What does it mean to sell short Eucrates Biomedical Acquisition stock? Short selling EUCR is an investing strategy that aims to generate trading profit from Eucrates Biomedical Acquisition as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Eucrates Biomedical Acquisition? A short squeeze for Eucrates Biomedical Acquisition occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EUCR, which in turn drives the price of the stock up even further. How often is Eucrates Biomedical Acquisition's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EUCR, twice per month. The most recent reporting period available is August, 15 2022. More Short Interest Resources from MarketBeat Related Companies: Yotta Acquisition Short Squeeze ESGEN Acquisition Short Squeeze Kairous Acquisition Short Squeeze Digital Health Acquisition Short Squeeze Moringa Acquisition Short Squeeze Cetus Capital Acquisition Short Squeeze Integral Acquisition Co. 1 Short Squeeze WinVest Acquisition Short Squeeze Qomolangma Acquisition Short Squeeze Arogo Capital Acquisition Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EUCR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss Ratings